American Cyanamid Company

Wyeth

Wyeth Holdings Corporation

Michael Greenstein

Guy T Carter

Margaret J Torrey

Donald B Borders

Joseph J Goodman

Nathan Magarvey

John Hucul

Mark Edward Ruppen

Raymond T Testa

David P Labeda

Haiyin He

Jason Arnold Lotvin

May D Lee

Amedeo A Fantini

William M Maiese

Darren Robert Abbanat

Valerie Sue Bernan

Arthur Bailey

Alan Gordon Sutherland

Phaik-Eng Sum

Russell Dushin

Howard Hancock Newman

Subas Man Sakya

Ping Cai

Taikwang M Lee

FangMing Kong

Bo Shen

Ting-Zhong Wang

Stanley Albert Lang

Arthur Emery Bailey

Howard Newman

Russell George Dushin

The present invention describes the identification of novel non-ribosomal peptide synthetases and associated biosynthetic genes from. The present invention further provides methods for generating novel compounds, such as antibiotics, from these synthetases and associated genes.

Non-ribosomal peptide synthetases and associated biosynthetic genes

The invention provides compounds of formulaWherein R, R, R, R, R, R, R, R, R, Rand Rare defined in the specification. These compounds are useful as antibiotic agents.

Glycopeptide antibiotics

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LLF28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F28249.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Agents and method of production thereof

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F28249.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Biologically pure culture of the microorganism, streptomyces

This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F2924.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.

Macrolide antibiotic compounds

Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora spp. calichensis NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Antitumor antibiotics (LL-E33288 complex)

Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

This invention provides a method for treating chronic respiratory disease, fowl cholera and necrotic enteritis in infected birds, by orally administering thereto a pharmaceutically effective amount of antibiotic LL-E19020.alpha., antibiotic LL-E19020.beta. or a physiologically acceptable salt thereof.

Method for controlling chronic respiratory disease, fowl cholera and

A biologically pure culture of Micromonospora purpureochromogenes ssp. Wuxiensis and its use in an aerobic fermentation process to produce the antibacterial and antiparasitic agent LL-D42067.alpha..

Process for producing antibiotic LL-D42067.alpha.

This invention relates to antibiotic LL-E19020.alpha. and LL-E19020.beta. derived from the microorganism Streptomyces lydicus subspecies tanzanius NRRL 18036, which are useful as an antibacterial agent.

Antibiotic LL-E19020 .alpha. and .beta.

Growing community of inventors

Suffern, NY, United States of America

Michael Greenstein